Clinton Group’s Haemonetics HAE Stock Holding History

Clinton Group’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-14,264	Closed	-$1.28M	–	272
2018 Q2	$1.28M	Buy	+14,264	New	+$1.2M	0.2%	171
2017 Q2	–	Sell	-12,980	Closed	-$527K	–	694
2017 Q1	$527K	Sell	12,980 -1,278	-9%	-$49.9K	0.03%	613
2016 Q4	$573K	Sell	14,258 -652	-4%	-$24.6K	0.03%	533
2016 Q3	$540K	Buy	14,910 +5,275	+55%	+$181K	0.03%	655
2016 Q2	$279K	Buy	+9,635	New	+$291K	0.01%	764

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Clinton Group's HAE Position: Q3 2018 in Review

Clinton Group sold out of Haemonetics (HAE) in Q3 2018, closing a stake of 14,264 shares — an estimated $1.28M sold.

Clinton Group first reported a position in HAE in Q2 2016 and held it in 5 quarters. The position peaked at $1.28M in Q2 2018. 292 funds tracked by Wall St. Rank hold HAE as of Q3 2018.

Clinton Group reported no remaining Haemonetics position as of Q3 2018 after selling out during the quarter.
Clinton Group sold 14,264 Haemonetics shares in Q3 2018, an estimated $1.28M.
Clinton Group first reported a position in Haemonetics in Q2 2016 and held it in 5 quarters.
Clinton Group's Haemonetics position peaked at $1.28M in Q2 2018.
292 funds tracked by Wall St. Rank held Haemonetics as of Q3 2018.

Based on Clinton Group's 13F filing for Q3 2018, filed 10 Oct 2018.